Clinical molecular imaging prostate image

PET imaging for Alzheimer's diseaseImprove outcomes with earlier detection

^{Image data courtesy of UMCG, Groningen, The Netherlands.}

Plaque buildup can be an early indicator of a devastating disease. The Alzheimer's Association estimates that 1 in 10 people in the US aged 65 and older live with Alzheimer's disease, and related brain changes often occur before the first symptoms are noticed. With ground-breaking advances in treatment technologies constantly emerging, early detection of neurodegenerative disease biomarkers is crucial.

PETNET Solutions

PETNET Solutions, Inc., a Siemens Healthineers company, is the leading provider for imaging centers nationwide. With a comprehensive portfolio of agents for imaging amyloid-beta plaque buildup and other neurological pathologies, and supplied by our reliable delivery network of high-energy radiopharmacies, PETNET is positioned to support the identification of neurodegenerative diseases like Alzheimer's Disease in its earliest stages.

Learn more about PETNET Solutions Inc.

Amyloid PET imaging for Alzheimer's

Patients with symptoms of cognitive impairment can be misdiagnosed with Alzheimer's disease. In fact, up to 1 in 5 patients clinically diagnosed with probable Alzheimer’s disease during life do not have Alzheimer’s disease pathology upon autopsy.^1,2

In a healthy brain, beta-amyloid protein fragments are broken down and removed from the brain. In a brain with Alzheimer’s disease, beta-amyloid protein fragments accumulate to form hard, insoluble plaques in between neurons.

Read the article “An examination of nuclear neurology in Japan”

Quantitative accuracy in PET imaging

Siemens Healthineers Molecular Imaging offers a strong foundation with over 35 years of innovation leadership in PET technology focusing on delivering high quality solutions that are intelligently engineered to be quantitative, accurate, and reproducible.

An accurate diagnosis starts with an accurate image in all dimensions. We recognize the core of a good image is an accurate detection system, which begins with optimized components. Biograph family of PET/CT scanners uses optimized components for the detection systems, Optiso High Definition (HD) and Optiso Ultra Dynamic Range (UDR) PET detectors. The design and configuration of the LSO crystals, the high-speed electronics, and the optimal acquisition matrix size, all enable physicians to attain the highest image quality and accurate quantifiable results. Combined with high-definition technologies, such as UltraHD•PET, the images produced allow the physician to diagnose with confidence.

Learn more about our Biograph family of PET/CT scanners

Optiso detector technology

Designed for optimum performance, our PMT based design offers high volumetric resolution 95-mm³, decreased partial volume effect, and superb image quality.

Crystal element technology

A fast, efficient scintillator, LSO is grown and cut in-house. Crystal elements deliver high isotropic spatial resolution; higher spatial resolution may result in improved lesion detectability.

Time of flight technology

Supports to better localize the event within a small range along each line of response (LOR). The better localization of each event using ToF reduces noise in the reconstructed image, while improving contrast and image clarity.

ultraHD•PET technology

Provides improved image signal-to-noise by utilizing timing information (time of flight) between the two PET coincidence events. Combined with the resolution recovery of HD•PET, this option can be used to enhance image quality.

^{Image data courtesy of Osaka City University, Japan.}

Our syngo®.PET Amyloid Plaque³ proprietary quantification software takes a patient’s PET amyloid exam and automatically registers it against a reference model of a PET amyloid brain. syngo.PET Amyloid Plaque software enables physicians to automatically calculate SUVr. Combined with visual assessment, these capabilities provide physicians with added information about amyloid-PET images.

PET radiopharmaceuticals doses — *PETNET's more than 45 PET radiopharmacies around the globe.*

Reliable delivery of PET imaging biomarkers

A closer look at the targeted PET biomarkers used for imaging neurodegeneration requires production and purification processes with higher sensitivities and complexities than your average oncological imaging agent.

Our dedicated team expertly operates our fully-integrated radiopharmacy network for the global production of imaging biomarkers for neurodegenerative diseases like Alzheimer's with over delivery reliability exceeding 99%.⁴

Ready to support your PET imaging business

Beyond the Foundation—grow your PET imaging business

It is essential to get the most out of your investment when introducing new clinical services. Your team works hard to avoid costly and unnecessary delays from incomplete plans, and to keep referrals coming through clear, correct interpretations.

PETNET Solutions leverages an experienced field staff, averaging more than 20 years of experience in the molecular imaging industry, to help with successful implementation of new imaging biomarkers. We are ready to support your efforts to plan, operate, and grow your PET imaging business.

Services & Support

Education & Training

Did this information help you?

Lim A, Tsuang D, Kukull W, et al. Clinico-Neuropathological Correlation of Alzheimer’s Disease in a Community-Based Case Series. J Am Geriatr Soc. 1999;47(5):564–569.

Petrovitch H, White LR, Ross GW, et al. Accuracy of Clinical Criteria for AD in the Honolulu-Asia Aging Study, a Population-Based Study. Neurology. 2001;57(2):226–234.

syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.

Data on file.